• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Marie Powers

Marie Powers

Articles

ARTICLES

Science for the season: BioWorld's 11th annual Holiday Gift Guide

Dec. 1, 2017
By Marie Powers
Thanksgiving doorbusters. Check. Black Friday blowouts. Check. Small business Saturday, Cyber Monday, Giving Tuesday. Check, check, check.
Read More

Science for the season: BioWorld’s 11th annual Holiday Gift Guide

Nov. 30, 2017
By Marie Powers
Thanksgiving doorbusters. Check. Black Friday blowouts. Check. Small business Saturday, Cyber Monday, Giving Tuesday. Check, check, check. It's only Dec. 1, with the major holidays some two weeks or more ahead, and major advertisers would have us believe we’re already shopped out. But the intrepid elves at BioWorld, along with some loyal readers and followers, have lined up fun selections for everyone on your list with our 11th annual Holiday Gift Guide. Heidi Chokeir, managing director at Canale Communications Inc., called the Foldscope kit “an AMAZING gift for the budding scientist in people’s lives.” Larger kits are already sold out...
Read More

With clinic in sight, Codiak doubles down with $76.5M series C

Nov. 30, 2017
By Marie Powers
Codiak Biosciences Inc. closed a $76.5 million series C, extending its runway in a big way following a combined series A/B that hit $92 million. Initial investors, including Arch Venture Partners, Flagship Pioneering, Fidelity Management and Research Co., the Alaska Permanent Fund and Alexandria Venture Investments, participated in the C round, joined by new investors that included Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, Ecor1 Capital and Casdin Capital.
Read More

VC helms Inozyme to pursue rare calcification play

Nov. 28, 2017
By Marie Powers
Axel Bolte's background in venture financing served him well when it came time to set up shop at Inozyme Pharma Inc. But his deep ties to academia were even more important to the company's formation. Entrée to technology discovered at Yale University could enable Inozyme to offer a distinctly new approach to treat rare calcification disorders.
Read More

Nothing remote about Outpost, which targets thick of the GI action

Nov. 27, 2017
By Marie Powers
"'Outpost' connotes a small force out on the frontier," Scott Byrd, newly named president and CEO of Outpost Medicine LLC, explained. It's a moniker the company takes seriously.
Read More

Genentech looks to disrupt hemophilia A space with Hemlibra approval

Nov. 17, 2017
By Marie Powers

More than three months ahead of its Feb. 23, 2018, PDUFA date, Hemlibra (emicizumab-kxwh), a bispecific monoclonal antibody that brings together factors IXa and X to mimic the role of factor VIII (FVIII) and restore blood clotting, was green-lighted by the FDA to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A who develop FVIII inhibitors.


Read More

Ultragenyx gets first approval, 'RARE' pediatric disease voucher

Nov. 16, 2017
By Marie Powers
A day ahead of its PDUFA date, Mepsevii (vestronidase alfa-vjbk, previously UX-003) won FDA approval to treat children and adults with the ultra rare inherited metabolic condition mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. The nod gave developer Ultragenyx Pharmaceutical Inc. its first commercial product and represented a first approval in the indication.
Read More

'Deep-Priming' technology adds new 'Torque' to cancer immunotherapy

Nov. 15, 2017
By Marie Powers
Torque Therapeutics Inc. emerged from the deep, disclosing a series A by Flagship Pioneering that was opened in conjunction with its founding in 2015 and, with a second tranche pulled down in August, amounts to $25 million.
Read More

Six for sixth: Zymeworks lures J&J to potential $1.45B bispecific deal

Nov. 14, 2017
By Marie Powers
Zymeworks Inc. nailed down its sixth strategic partnership, luring Johnson & Johnson unit Janssen Biotech Inc. to a potential $1.45 billion global license to research, develop and commercialize up to six bispecific antibodies directed to Janssen therapeutic targets using Zymeworks' Azymetric and EFECT (Effector Function Enhancement and Control Technology) platforms.
Read More

Israel's Entera Bio goes after U.S. listing in $50M IPO

Nov. 13, 2017
By Marie Powers
Entera Bio Ltd., established in June 2010 as a joint venture of fellow Israeli firms DNA Biomedical Solutions and Oramed Pharmaceuticals Inc., is seeking to raise up to $50 million, including overallotments, in an IPO, with a listing on Nasdaq under the ticker ENTX. The Jerusalem-based firm is developing oral formulations of teriparatide (parathyroid hormone, or PTH, 1-34) to treat hypoparathyroidism (EB-612) and osteoporosis (EB-613). Oppenheimer & Co. is the sole bookrunner on the deal, which was not priced.
Read More
View All Articles by Marie Powers

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 8, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe